Efficacy of plasma exchange in the therapy of recurrent pregnancy-associated atypical hemolytic-uremic syndrome


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Pregnancy-associated atypical hemolytic-uremic syndrome (aHUS) is characterized by an aggressive avalanche-like course and an extremely poor prognosis with fulminant thrombotic microangiopathy (TMA), whereas targeted therapy with a complement-blocking drug is always impossible in the first 24 hours. There are very few cases of recurrent pregnancy-associated aHUS in the modern literature; in this connection it is important to display the management of patients with the second disease episode that has developed during pregnancy. In the era of eculizumab, the role of plasma exchange in verified aHUS is becoming increasingly limited. Just the same, when eculizumab is not available, plasma exchange remains the only treatment option. Case report. The paper presents the experience in successfully treating two consecutive pregnancy-associated aHUS episodes manifested after delivery in one patient, by using only plasma exchange, which showed a favorable outcome, including complete recovery of renal function. Conclusion. Different types of TMA in pregnancy are fulminant and represent a life-threatening condition for the mother. In this condition, the most urgent issue is the timely initiation of appropriate therapy. The presented observation of two aHUS episodes demonstrates difficulties in choosing a treatment policy and in making a rapid differential diagnosis, even when there is only one episode of TMA in the history. The discussion lists the recommended treatment regimens, as well as the possibility of a favorable outcome with timely initiation of plasma therapy

Full Text

Restricted Access

About the authors

Tatyana V. Kirsanova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: a_tatya@mail.ru
PhD, Senior Researcher of the Department of Transfusiology and Extracorporeal Hemocorrection

Tatiana A. Fedorova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: tfedorovai@mail.ru
MD, professor, Head of the Department of Transfusiology and Extracorporeal Hemocorrection

Samira R. Gurbanova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: gursam8i@mail.ru
PhD, researcher of the Department of Extracorporal Methods of Treatment and Detoxification

Aleksey V. Pyregov

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: a_pyregov@oparina4.ru
MD, Head of the Department of Anesthesiology-Resuscitation

Maria A. Vinogradova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: mary-grape@yandex.ru
PhD, Head of Department of Reproductive Hematology and Clinical Hemostasiology

References

  1. Fakhouri F., Scully M., Provot F., Blasco M., Coppo P., Noris M. et al. Management of thrombotic microangiopathy in pregnancy and postpartum: Report From an International Working Group. Blood. 2020; 136(19): 2103-17. https://dx.doi.org/10.1182/blood.2020005221.
  2. Gupta M., Govindappagari S., Burwick R.M. Pregnancy-associated atypical hemolytic uremic syndrome: A systematic review. Obstet. Gynecol. 2020; 135(1): 46-58. https://dx.doi.org/10.1097/AOG.0000000000003554.
  3. Scully M., Hunt B.J., Benjamin S., Liesner R., Rose P., Peyvandi F. et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br. J. Haematol. 2012; 158(3): 323-35. https://dx.doi.org/10.1111/j.1365-2141.2012.09167.x.
  4. Birkhoelzer S., Belcher A., Peet H. Diagnostic dilemma: Severe thrombotic microangiopathy in pregnancy. J. Intensive Care Soc. 2017; 18(4): 348-51. https://dx.doi.org/10.1177/1751143717715969.
  5. Appel G.B. Thrombotic microangiopathies: Similar presentations, different therapies. Cleve Clin. J. Med. 2017; 84(2): 114-30. https://dx.doi.org/10.3949/ccjm.84gr.17001.
  6. Elayoubi J., Donthireddy K., Nemakayala D.R. Microangiopathies in pregnancy. BMJ Case Rep. 2018; 2018: bcr-2017-221648. https://dx.doi.org/10.1136/bcr-2017-221648.
  7. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2013; 368(23): 2169-81. https://dx.doi.org/10.1056/ NEJMoa1208981.
  8. Padmanabhan A., Connelly-Smith L., Aqui N., Balogun R.A., Klingel R., Meyer E. et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J. Clin. Apher. 2019; 34(3): 171-354. https://dx.doi.org/10.1002/jca.21705.
  9. Schwartz J., Padmanabhan A., Aqui N., Balogun R.A., Connelly-Smith L., Delaney M. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: The Seventh Special Issue. J. Clin. Apher. 2016; 31(3): 149-62. https://dx.doi.org/10.1002/jca.21470.
  10. Huerta A., Arjona E., Portoles J., Lopez-Sanchez P., Rabasco C., Espinosa M. et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018; 93(2): 450-9. https://dx.doi.org/10.1016/J.kint.2017.06.022.
  11. Eddy A.A., Geary D.F., Balfe J.W., Clark W.F., Baumal R. Prolongation of acute renal failure in two patients with hemolytic-uremic syndrome due to excessive plasma infusion therapy. Pediatr. Nephrol. 1989; 3(4): 420-3. https://dx.doi.org/10.1007/bf00850219.
  12. Filler G., Radhakrishnan S., Strain L., Hill A., Knoll G., Goodship T.H. Challenges in the management of infantile factor H. associated hemolytic uremic syndrome. Pediatr. Nephrol. 2004; 19(8): 908-11. https://dx.doi.org/10.1007/s00467-004-1526-9.
  13. Laurence J., Haller H., Mannucci P.M. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin. Adv. Hematol. Oncol. 2016; 14(Suppl. 11): 2-15.
  14. Hou R., Tian W., Qiao R., Zhang J. Efficacy of albumin and compounded plasma for plasma exchange in acquired thrombotic thrombocytopenic purpura. J. Clin. Apher. 2020; 35(3): 154-62. https://dx.doi.org/10.1002/jca.21771.
  15. Кирсанова Т.В., Федорова Т.А., Гурбанова С.Р., Балакирева А.И., Рогачевский О.В., Виноградова М.А., Завьялова И.В. Ургентный плазмообмен при лечении тромботической микроангиопатии в послеродовом периоде у женщин. Анестезиология и реаниматология. 2020; 5: 85-91. https://dx.doi.org/10.17116/anaesthesiology202005185.
  16. Claes K., Massart A., Collard L., Weeker L., Goffin E., Pochet Jean-M. et al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin. Belg. 2018; 73(1): 80-9. https://dx.doi.org/10.1080/17843286.2017.1345185.
  17. Gupta M., Feinberg B.B., Burwick R.M. Thrombotic microangiopathies of pregnancy: differential diagnosis. Pregnancy Hypertens. 2018; 12: 29-34. https://dx.doi.org/10.1016/j.preghy.2018.02.007.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies